Pinned Tweet
For 2,000 years, physicians believed disease lived in the blood. They were wrong about almost everything except that.
My book Old Blood, New Life (with Dr. Dobri Kiprov) tells how cleaning the blood became real medicine, and where plasma exchange goes next: Alzheimer's, aging, cancer immunotherapy, microplastics.
amazon.com/dp/B0HH86RWKJ
3
604
While I disagree, I can almost understand the pushback to living until 120. It feels foreign and impossible so why waste effort on it, right?
But to make the argument that we shouldn’t try to be healthy into our 80s and 90s is crazy.
The NYT wrote this article to give people institutional permission to opt out of health.
They're moralizing inaction, framing it as wisdom granting permission to feel righteousness.
Movements follow three stages:
> fascination
> evangelism
> backlash
Longevity is in the backlash stage. The skepticism will do a lot to clean up the industry and bridge to the next stage where a lot of what exists today will slough off and new forms of legitimacy will emerge.
Allen Green, MD retweeted
That's not how it works. No one jumps straight to insulin. No guideline recommends that.
Guidelines:
1. Lifestyle changes
2. Metformin (usa)
3. Metformin+SGLT2i (uk)
4. GLP1s
5. DPP-4i
6. Sulfonylureas
7. Thiazolidinediones
8. Various Secretagogues (Prandin, Starlix,etc)
9. Other oral meds
10. Maybe insulin
Doctor: "Your HbA1c is still climbing on the metformin and the gliclazide. It's time to start insulin."
Patient: "What's actually wrong with me?"
Doctor: "Type 2 diabetes. Your cells don't respond to insulin properly, so the sugar stays in the blood."
Patient: "They don't respond to insulin."
Doctor: "Correct."
Patient: "And you're giving me insulin."
Doctor: "More of it, to push past the resistance."
Patient: "If my key stops turning in the lock, do you cut me a bigger key?"
Doctor: "The analogy isn't perfect. Insulin still moves glucose out of the blood."
Patient: "Into where?"
Doctor: "Muscle, liver. And fat tissue."
Patient: "So it makes me fatter."
Doctor: "Weight gain is a common side effect, yes."
Patient: "Does fat make the resistance better or worse?"
Doctor: "Worse."
Patient: "So next year?"
Doctor: "We'd adjust the dose."
Patient: "Up."
Doctor: "Typically."
Patient: "My brother-in-law started on twenty units. He's on ninety and he's four stone heavier."
Doctor: "It's a progressive condition."
Patient: "It's progressive because the treatment feeds it. What makes the blood sugar in the first place?"
Doctor: "What you eat. Carbohydrate, mainly."
Patient: "Then I'll stop putting it in rather than paying a man to shove it into my belly. Keep the pen. Write 'declined, cut the bread' and underline it."
Allen Green, MD retweeted
The statin dementia study going viral is real, but look at who got the statins. Before any statistical adjustment, statin users had hypertension 49.5% of the time vs 16.1% for non-users, diabetes 18.4% vs 3.7%, and coronary disease 17.5% vs 3.6%.
That's the core problem with this design. People get statins because their blood vessels are already in trouble, and blood vessel trouble is a dementia risk on its own. The authors say it themselves: confounding by indication may remain, and smoking and alcohol were left out of the prescription analyses.
The CoQ10 angle is thinner than it sounds. CoQ10 was never measured. They used a single reading of a protein called COQ7 in a subset of people, and it explained 8.2% of the link.
Their own conclusion is that this needs more work before informing clinical decisions about statin therapy. Don't change a prescription because of a post, including this one.
Brand new study just dropped (published Oct 29, 2026 in Frontiers in Pharmacology).
A massive new analysis from two of the world’s largest biomedical databases just linked statin use to roughly double the risk of dementia.
Researchers looked at the All of Us Research Program (83,355 adults, including over 31,000 statin users, followed through 2023) and the UK Biobank (173,282 adults, including nearly 44,000 statin users). After balancing groups for age, BMI, APOE status, comorbidities, and other factors using inverse probability of treatment weighting, statin users showed adjusted hazard ratios of 2.22 (All of Us) and 2.54 (UK Biobank) for incident dementia.
The association held across Alzheimer’s disease, vascular dementia, and other subtypes. High-intensity statins carried an additional ~14% higher risk compared with moderate-to-low intensity therapy. Incidence rates were higher in the discovery cohort (64.9 vs 30.7 per 10,000 person-years) than in the replication cohort, but the relative increase was consistent.
In an exploratory mediation analysis, a modest portion (8.2%) of the association appeared to run through lower levels of coenzyme Q7—a protein involved in CoQ10 biosynthesis. Lower COQ7 was itself linked to higher dementia odds. The pathway through LDL-C was not statistically significant. The authors note this is hypothesis-generating and that direct CoQ10 was not measured.
This is observational data, not a randomized trial, so it cannot prove causation. Residual confounding (including why people were prescribed statins) remains possible, and the literature on statins and cognition has been mixed. Still, the scale, the replication across two independent cohorts, the intensity-dependent pattern, and the COQ7 signal make it hard to ignore.
This is the kind of result that makes people who have been skeptical of long-term statin use for primary prevention sit up and take notice—especially given the CoQ10 connection many clinicians have quietly acknowledged for years.
The full paper is open access: frontiersin.org/journals/pha…
Allen Green, MD retweeted
Carl Jung was right when he said: in my experience, I have found that the solutions to all of life’s most intractable problems are not found through any form of intellect or cleverness.
They are solved simply by moving on.
This is a clot that formed in the machine. EBOO has no filtration mechanism. It is not FDA-cleared and operates in a gray area that borders on being illegal.
allenpgreenmd.com/blog/is-eb…
4
182
Allen Green, MD retweeted
Considering Japan for Vx injury or LC? Update on my journey:
I wanted to share an update because quite a bit has changed since I returned from Japan.
Unfortunately, my health has continued to decline. Recent immune testing has shown that my immunodeficiency is more significant than we originally understood, including inadequate protective antibody responses to pneumococcal bacteria. My autoimmune markers remain elevated, and more recent testing also shows increasing inflammatory activity.
At the same time, the neuropathy has continued to worsen. The burning pain and numbness are spreading, and my headaches have become significantly worse. Because of the headaches and my existing cervical instability and vascular issues, further vascular imaging of my neck and brain may be needed to evaluate for additional compression.
This week I am traveling back to Utah, where much of my specialty medical team is located, for my first two IVIG (intravenous immunoglobulin, made from pooled donor plasma) infusions on back-to-back days. These treatments will be given in an infusion center. My physicians hope IVIG may help address the antibody deficiency and potentially some of the immune-mediated inflammation and neuropathy as well.
I have also connected with members of the React19 community who have experienced substantial improvement with IVIG. Their experiences give me some hope while also reminding me that everyone responds differently.
Travel adds another layer of expense—gas, food, medical costs and the trip itself—but thankfully I will be able to stay with family, so lodging is covered.
Another big change has been accepting that I need a motorized wheelchair.
I fought that reality for a long time. I can no longer make the short distance to our mailbox or walk through a grocery store. Buying the chair felt like admitting something I wasn't ready to admit.
But it has also given something back to me. Special thanks to Kelsey for helping me see this and allow me to test drive your wheel;)
I can be outside with Brew, Greg and Kai. I was able to accompany Kai on his first day of school. Those moments matter more than I can explain.
The chair represents loss, but it has also allowed me to participate in pieces of my family's life again.
I also want to give a very honest and objective update about the treatment I underwent in Japan, particularly for people who may currently be considering going.
Before I left, Dr. Jordan Vaughn, my naturopath Dr. Costa, and my immunologist Dr. Jones intentionally ordered extensive laboratory testing so that we would have objective data to compare before and after treatment.
Relevant testing was performed before Japan on March 18 and July 15, 2026. Post-treatment testing was performed after my return on August 25, with additional redraws on September 10 when several specimens—including MMP-9—could not be adequately processed from the earlier draws.
One of my goals in going to Japan was not only to get better, but to determine whether the treatment produced measurable changes that might help validate the program and potentially help other people with Long COVID.
So far, the opposite of what I hoped to document has occurred.
My post-treatment testing has not shown the objective improvement I hoped to see. Instead, several inflammatory markers we were following before treatment have increased, and several cytokines that had previously been below the laboratory cutoff are now elevated.
For example, comparing the most recent valid pre-treatment values from July with my September 10 post-treatment testing:
• IL-12 increased from 4.7 to 9.9 pg/mL.
• IL-5 increased from <2.1 to 3.3 pg/mL and is now elevated.
• IL-17 increased from <1.4 to 1.7 pg/mL and is now elevated.
• TNF-alpha increased from 6.0 to 16.0 pg/mL and is now elevated.
• TGF-β1 increased from 12,367 to 33,676 pg/mL and is now above the laboratory reference range.
• MMP-9, which was already elevated at 1,283 ng/mL before Japan, increased further to 1,519 ng/mL.
Some of the planned July 15 and August 25 specimens were insufficient for certain tests, which is why the September 10 redraws were necessary. For those markers, I am comparing the September results with the most recent valid pre-Japan measurements rather than pretending we have data points that we do not.
These are not simply changes in how I feel. They are measurable laboratory findings that my medical team and I intentionally tracked before and after treatment.
At the same time, clinically, my neuropathy, burning pain, numbness, headaches and overall function have continued to decline.
I want to be equally clear about what these results do NOT prove.
They do not establish that the treatments in Japan caused these changes. Long COVID is complicated, laboratory values can fluctuate, and there are many potential variables.
What I can say is that my own objective pre- and post-treatment data have not demonstrated the improvement I went to Japan hoping to document. In several areas, the measurable trend has instead moved in the opposite direction.
The treatment itself was also not without significant risk. My central-line placement resulted in a pneumothorax requiring hospitalization and a chest tube.
Since August, I have personally spoken with several patients who initially experienced improvement after treatment and later experienced relapsing symptoms, in some cases within only a few months of completing treatment. This is information I wish I had understood more clearly before making my decision.
Knowing what I know now—including my clinical course, the complication I experienced, the pre- and post-treatment laboratory findings, and what I have since learned from other patients—I would NOT make the same decision to go.
I feel a responsibility to say that clearly for anyone currently considering this experiment.
I believe patients deserve to understand not only the possibility of improvement, but also the procedural risks, the uncertainty surrounding durability of response, and the possibility that symptoms may return even after an initial improvement.
I went to Japan hoping not only to improve my own health, but also to gather information that might help other people suffering from Long COVID.
I genuinely hoped my pre- and post-treatment testing would help validate the program.
Being transparent when the results do not support what I hoped to find is part of that responsibility too.
Meanwhile, Greg is still unemployed following the layoffs that affected him and his team. He is looking for work every day—networking, contacting leads, applying, and doing everything he can to find the right opportunity. It has made an already difficult financial situation even harder.
I know these are difficult economic times for so many people. I never take a donation, share, message, prayer, or offer of help for granted. We are deeply grateful. I certainly don't want anyone to suffer hardship because of me.
If anyone has unused airline miles or travel points and would be willing to use them toward one of my medical trips, that could also be tremendously helpful as travel to specialists continues.
For anyone who prefers Venmo:
@april-amber-theisen
Go Fund Me:
gofundme.com/f/help-april-ac…
gofund.me/b7f2c2cb6
Thank you for continuing to stand beside our family.
I am still searching for answers, still following the data—even when it isn't the answer I hoped for—and still hoping that some combination of science, persistence and time will give me more of my life back.
@TheRebelPatient @DrMaryBowden @Burning_mama47 @kelseyshields08 @evanfgeorge @EdogawaPatients @KenCaptn20114
Four plasma exchange sessions, and all 11 organ-system epigenetic clocks came back lower. But not evenly: immune fell 8.2 years, blood fell 0.2.
Two systems the Yale framework clusters together came out 7.1 years apart.
One patient. What explains the spread?
2
134
Allen Green, MD retweeted
Replying to @CynicalPublius
A brief summary of how I see it as a Hematologist
To clarify one thing ... the ONLY way he gets lifelong treatment is if he has an underlying condition - which is not anyones fault, and it was simply the clot that brought it to attention
xitter.gq/PaleoOnc/status/211238…
Replying to @JamesRHarrigan
There is a lot of misinformation going on around this
To set (some) of the record straight ...
(all based on publicly available info, which could be wrong)
Oct 4 - calf injury - (no known clot, and not necessarily suspected)
Oct 10 - US in London shows what is reported to be a *superficial* vein thrombosis (SVT)
SVT are considering "low risk" clots which do not always require treatment (anticoagulation).
Post-traumatic clots are especially low-risk, because it is assumed that the injury caused the clot, and the vein will heal naturally as the injury heals.
This is NOT controversial
As far as "do not sleep" - this is pure rumor mill.
We NEVER tell clot patients to NOT sleep.
It is not a thing.
Clot patients can sleep without fear. Period.
Local docs recommended follow-up US in a few days, which is reasonable. It is actually optional, but a good CYA recommendation, especially for a VIP who opted not to treat the SVT upfront.
Oct 11 - Played in the game. We LIKE to see these patients mobile. Assuming he had no symptoms of worsening, this would be fine. I would assume local med staff were watching the leg.
Oct 11 - flew home. Again, assuming no new symptoms, this is fine. I would have advised him to walk about the plane, for better circulation, but otherwise, for an SVT, there is no issue with flying. You do not need to treat low-risk SVT
Oct 14 - He gets the follow-up US which was advised.
"Movement" of clot is reported
"Movement" is not a diagnosis.
But safe to assume it got worse.
This was not a foregone conclusion.
Many SVT get better. Some do not.
It is impossible to know if playing or flying contributed, or if it would have happened anyway.
Oct 19 - the significant clot and PE are announced.
He will be fine
For all the bluster, what actually happened?
They gambled 6 weeks of anticoagulation for a low-risk clot but out of play for 6 weeks (too dangerous to play football on blood thinners)
They lost the bet and get 6-12mo of blood thinners, taking him out for a very long time.
Depending on testing they may or may not do, they may decide he needs lifelong blood thinners. This is an individual decision based on individual factors and would not be anyone's fault, just his base health conditions that we will probably never know (nor do we need to)
Bottom line - there is a series of decisions which are all individually responsible and not careless. You make risk benefit decisions all the time without knowing the future.
Just like when the weatherman says "10% chance of rain" ... if it rains, he was not an idiot. Sometimes the rare thing happens.
Added - a story
xitter.gq/PaleoOnc/status/211233…
“Mr Irrelevant”…
#49ers QB Brock Purdy now has the highest career passer rating in NFL history among QBs with at least 1,500 attempts:
1) Brock Purdy: 105.4
2) Lamar Jackson: 102.7
3) Aaron Rodgers: 101.8
The final pick in the NFL Draft. Alone on top.
2
109
Allen Green, MD retweeted
Ok this part makes zero sense and now I do question why he played after seeing this part of the report. That much sleep deprivation can have a similar effect to being drunk in terms of awareness and neuromuscular control.
There’s nothing inherently dangerous about sleeping while having a superficial clot. Immobility (venous stasis) can cause clots to get worse, but that’s why you are often advised to just sleep with the leg elevated.
I’ve NEVER heard of someone being told to avoid sleep after a superficial blood clot diagnosis and the short term effect of that sleep deprivation is a terrible thing to play football with.
Jalen Hurts reportedly went roughly 36 hours without sleep after doctors diagnosed him with a superficial blood clot in London and advised him not to sleep as a precaution.
He still started against the Jaguars, throwing for 220 yards and a TD.
(@TomPelissero)
Yet another way therapeutic plasma exchange and similar Apheresis modalities could play a larger role in cancer treatment.
Neutrophil extracellular traps are emerging as participants in multiple steps of metastasis—from dissemination to awakening dormant cells.
pubmed.ncbi.nlm.nih.gov/4189…
Agree with this 100%. This is what matters in scientific writing.
We don't ask whether a model touched their prose. We ask authors to own every word.
@JACCJournals parted w/ICMJE & doesn't require disclosure of AI writing help: the rule is unenforceable, biased, & not good for medical communication.
My Editor's Page: jacc.org/doi/10.1016/j.jacc.…
1
142
Allen Green, MD retweeted
GLP1s looking more and more like longevity drugs
New paper @Nature: Semaglutide recapitulates many of the benefits of caloric restriction in female mice & extends lifespan by almost 100 days. Males not yet tested for lifespan
Below: Red traces = mouse movement
It's out.
Old Blood, New Life is a book I wrote with my colleague Dr. Dobri Kiprov about something I do every day: plasma exchange, where a patient's blood is drawn, separated, cleaned of what has built up in it, and returned.
It starts four thousand years ago with bloodletting and the four humors, which turned out to be a brilliant wrong answer, and follows the idea forward to where it stands now. Proven medicine in autoimmune disease. Promising and still unproven in Alzheimer's and in aging itself. The book is careful about which is which, because very little in the longevity world is.
No medical background needed. It was written for readers, not for the journals.
If you read it and it lands, an Amazon review helps a new book more than almost anything else.
amazon.com/dp/B0HH86RWKJ
1
6
277
Allen Green, MD retweeted
the aca was a huge boon to payers and health systems
but physicians got more bureaucracy
and consumers got higher premiums and deductibles
David Friedberg says Moderna is charging $500K for a ‘cancer vaccine’ that already exists
"What frustrates me the most about all of this, everyone's kind of lauding this as some unique breakthrough and special and powerful. It's not, a lot of people are going to places like Montana and getting peptides printed for their particular cancer sequence, making their own neo-antigens, and getting cured of their cancer.”
“You can pay someone $50,000 to do this for you today. There's a lot of clinics that will do it. And it's not a special FDA-approved drug. So why is Moderna saying that they're going to charge $500,000 for this?"
"I don't think that this technique, which has been developed through several decades of iteration, funded by NIH and other public funding dollars, should now be patented, FDA-approved, and charged half a million dollars for people to get treated for this."
"A private pharmaceutical company has seen their market cap go from $20 billion to $60 billion because they went through this regulatory process to create what, in my mind, is a form of regulatory capture.”
“They’re making the case that it's all about safety and trials, when fundamentally there's an underlying technique that was funded by a lot of public research dollars that I think should be more open-sourced, more ubiquitous. Every hospital should be trained on how to do this process to treat cancer patients.”
Therapeutic Plasma Exchange has been shown in small trials by the Mayo Clinic to improve outcomes of Keytuda and similar drugs.
It works by removing cancer produced decoy molecules that make the drugs ineffective.
I'd love to see results from TPE+Keytruda+ the moderna mRNA vaccine.
ELI5: Moderna made a cancer vaccine that is custom for every person.
Doctors read the DNA of your tumor, find what makes it unique, then make an mRNA shot that teaches your immune system, “Attack cells that look like this.”
They combine it with Keytruda, a drug that helps stop cancer from hiding from your immune system.
It just succeeded in a Phase 3 melanoma trial.
Not a cure for all cancer. But a pretty huge idea if it works for other cancers too.
2
3
475































